(CELH) Celsius Holdings - NASDAQ
Sector: Consumer Defensive | Industry: Beverages - Non-Alcoholic | Exchange: NASDAQ (USA) | Market Cap: 7.444m USD | Total Return: -34.3% in 12m
Avg Turnover: 276M
Qual. Beats: 0
Rev. Trend: 89.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality
Celsius Holdings, Inc. (NASDAQ: CELH) is a U.S.-based functional energy drink company that develops, manufactures, markets, sells, and distributes its products across the United States, North America, Europe, Asia Pacific, and other international markets. The company offers a range of products including ready-to-drink energy beverages, hydration powders and sticks, and nutrition and wellness items under the CELSIUS, Alani Nu, and Rockstar brand names, with sub-lines such as CELSIUS ESSENTIALS (formulated with amino acids) and CELSIUS Hydration (zero-sugar electrolyte powders in fruit-forward flavors). The company was founded in 2004, is headquartered in Boca Raton, Florida, and operates a broad omnichannel distribution network spanning direct-to-store delivery, independent distributors, supermarkets, convenience and drug stores, food service providers, mass merchants, fitness centers, club and vitamin specialty stores, and e-commerce platforms.
The company operates within the Consumer Staples sector, specifically the Soft Drinks & Non-alcoholic Beverages sub-industry, a mature and highly competitive category traditionally dominated by large incumbents such as Coca-Cola and PepsiCo. Within this space, Celsius has positioned itself in the faster-growing functional and better-for-you beverage segment, targeting active-lifestyle and fitness-oriented consumers through fitness-center and specialty-channel distribution as well as digital channels.
- Alani Nu acquisition accelerates revenue growth and expands consumer base
- Pepsi distribution partnership drives shelf space expansion nationally
- GLP-1 drug adoption pressures functional beverage category demand
| Net Income: 173.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -5.39 > 1.0 |
| NWC/Revenue: 25.72% < 20% (prev 74.75%; Δ -49.03% < -1%) |
| CFO/TA 0.06 > 3% & CFO 329.8m > Net Income 173.7m |
| Net Debt (1.91b) to EBITDA (298.4m): 6.39 < 3 |
| Current Ratio: 1.73 > 1.5 & < 3 |
| Outstanding Shares: last quarter (259.8m) vs 12m ago 9.53% < -2% |
| Gross Margin: 49.62% > 18% (prev 50.43%; Δ -0.81% > 0.5%) |
| Asset Turnover: 84.61% > 50% (prev 71.48%; Δ 13.13% > 0%) |
| Interest Coverage Ratio: 4.31 > 6 (EBIT TTM 262.4m / Interest Expense TTM 60.8m) |
| A: 0.15 (Total Current Assets 1.81b - Total Current Liabilities 1.05b) / Total Assets 5.16b |
| B: 0.05 (Retained Earnings 272.0m / Total Assets 5.16b) |
| C: 0.07 (EBIT TTM 262.4m / Avg Total Assets 3.51b) |
| D: 0.32 (Book Value of Equity 1.25b / Total Liabilities 3.91b) |
| Altman-Z'' = 1.98 = BBB |
| DSRI: 1.45 (Receivables 832.4m/256.4m, Revenue 2.97b/1.33b) |
| GMI: 1.02 (GM 50.43% / 49.62%) |
| AQI: 3.18 (AQ_t 0.63 / AQ_t-1 0.20) |
| SGI: 2.23 (Revenue 2.97b / 1.33b) |
| TATA: -0.03 (NI 173.7m - CFO 329.8m) / TA 5.16b) |
| Beneish M = -0.47 (Cap -4..+1) = D |
As of June 28, 2026, the stock is trading at USD 29.85 with a total of 9,862,150 shares traded. Over the past week, the price has changed by -3.08%, over one month by +0.61%, over three months by -16.13% and over the past year by -34.28%.
Current recommended Stop Loss: 27.90 (which is 6.5% or 1.2 ATR below the current price).
Celsius Holdings has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CELH.
- StrongBuy: 8
- Buy: 6
- Hold: 6
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 60.6 | 102.9% |
P/E Trailing = 67.7209
P/E Forward = 18.797
P/S = 2.5077
P/B = 5.9518
P/EG = 0.2963
Revenue TTM = 2.97b USD
EBIT TTM = 262.4m USD
EBITDA TTM = 298.4m USD
Long Term Debt = 668.9m USD (from longTermDebt, last quarter)
Short Term Debt = 7.00m USD (from shortTermDebt, last quarter)
Debt = 2.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 19.7m
Net Debt = 1.91b USD (calculated: Debt 2.46b - CCE 549.2m)
Enterprise Value = 9.35b USD (7.44b + Debt 2.46b - CCE 549.2m)
Interest Coverage Ratio = 4.31 (Ebit TTM 262.4m / Interest Expense TTM 60.8m)
EV/FCF = 31.94x (Enterprise Value 9.35b / FCF TTM 292.8m)
FCF Yield = 3.13% (FCF TTM 292.8m / Enterprise Value 9.35b)
FCF Margin = 9.86% (FCF TTM 292.8m / Revenue TTM 2.97b)
Net Margin = 5.85% (Net Income TTM 173.7m / Revenue TTM 2.97b)
Gross Margin = 49.62% ((Revenue TTM 2.97b - Cost of Revenue TTM 1.50b) / Revenue TTM)
Gross Margin QoQ = 48.31% (prev 47.37%)
Tobins Q-Ratio = 1.81 (Enterprise Value 9.35b / Total Assets 5.16b)
Interest Expense / Debt = 2.48% (Interest Expense 60.8m / Debt 2.46b)
Taxrate = 13.84% (27.9m / 201.6m)
NOPAT = 226.1m (EBIT 262.4m * (1 - 13.84%))
Current Ratio = 1.73 (Total Current Assets 1.81b / Total Current Liabilities 1.05b)
Debt / Equity = 1.96 (Debt 2.46b / totalStockholderEquity, last quarter 1.25b)
Debt / EBITDA = 6.39 (Net Debt 1.91b / EBITDA 298.4m)
Debt / FCF = 6.51 (Net Debt 1.91b / FCF TTM 292.8m)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.95% (Net Income 173.7m / Total Assets 5.16b)
RoE = 7.51% (Net Income TTM 173.7m / Total Stockholder Equity 2.31b)
RoCE = 8.80% (EBIT 262.4m / Capital Employed (Equity 2.31b + L.T.Debt 668.9m))
RoIC = 5.70% (NOPAT 226.1m / Invested Capital 3.96b)
WACC = 8.47% (E(7.44b)/V(9.90b) * Re(10.56%) + D(2.46b)/V(9.90b) * Rd(2.48%) * (1-Tc(0.14)))
Discount Rate = 10.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 26.26 | Cagr: 5.19%
[DCF] Terminal Value 77.58% ; FCFF base≈258.0m ; Y1≈295.7m ; Y5≈435.2m
[DCF] Fair Price = 17.63 (EV 6.41b - Net Debt 1.91b = Equity 4.51b / Shares 255.6m; r=8.47% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 89.91 | Revenue CAGR: 38.68% | SUE: 0.32 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=+0.09% | Revisions=-60% | Analysts=18
EPS next Quarter (2026-09-30): EPS=0.44 | Chg30d=-0.23% | Revisions=-71% | Analysts=18
EPS current Year (2026-12-31): EPS=1.63 | Chg30d=+0.15% | Revisions=+10% | GrowthEPS=+21.7% | GrowthRev=+33.0%
EPS next Year (2027-12-31): EPS=2.03 | Chg30d=-0.25% | Revisions=-5% | GrowthEPS=+24.8% | GrowthRev=+9.8%
[Analyst] Revisions Ratio: -71%